Comparison of three different immunoassay methods for the evaluation of intact parathyroid hormone levels in hemodialysis patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 3, 2011, Pages 227-231

  Ates, Fatih ^a   Koken, Tulay ^a   Demir, Serap ^a   Kahraman, Ahmet ^a   Dogan, Nurhan ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

Author keywords

chronic kidney disease; hemodialysis; immunoassay; mineral and bone disorder; Parathyroid hormone

Indexed keywords

PARATHYROID HORMONE;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; ELECTROCHEMILUMINESCENT IMMUNOASSAY; ENZYME IMMUNOASSAY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

ADULT; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS;

EID: 79954501367     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.555563     Document Type: Article

References (20)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and reatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1 - 130
2. D'A mour P, Labelle F, Lecavalier L, Plourde V, Harvey D. Infl uence of serum Ca concentration on circulating molecular forms of PTH in three species. Am J Physiol 1986;241: E680 - 7.
3. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D 'Amour P. Accumulation of a non-(1-84) molecular form detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-9. (Pubitemid 26380397)
4. D'A mour P, Palardy J, Bashali G, Mallette LE, DeLean A, Lepage R. Modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J Clin Endocrinol Metab 1992;75:525-32.
5. Freitag J, Martin K, Huruska K, Anderson C, Conrades M, Ladenson J, Klahr S, Slatopolsky E. Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 1978;298:29-32. (Pubitemid 8256370)
6. Ure ñ a Torres P. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006;70:240-3.
7. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D 'Amour P. A non-(1-84) PTH circulating fragment interferes signifi cantly with intact PTH measurement by commercial assays in uremic samples. Clin Chem 1998; 44:805-9. (Pubitemid 28176023)
8. Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52: 1771-6. (Pubitemid 44330713)
9. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10. (Pubitemid 16134762)
10. D'A mour P, Brossard JH, Rakel A, Rousseau L, Albert C, Cantor T. Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 2005;51:169-76. (Pubitemid 40024027)
11. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Mange M, Myara J, Parent X, Plouvier E, Houillier P. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345-50. (Pubitemid 44086584)
12. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358-63.
13. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoune T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287-93. (Pubitemid 29072230)
14. John MR, Goodman WG, Gao P, Cantor T, Salusky IB, J ü ppner H. A novel immunoradiometric assay detects fulllength human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrino Metab 1999;84:4287-90. (Pubitemid 30644232)
15. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Infl uence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003;18:759-68. (Pubitemid 36432259)
16. Estepa JC, Lopez I, Felsenfeld AJ, Gao P, Cantor T, Roriguez M, Aguilera-Tejero E. Dynamics of secretion and metabolism of PTH during hypo- and hypercalcaemia in the dog as determined by the intact 'and whole 'PTH assays. Nephrol Dial Transplant 2003;18:1101-7. (Pubitemid 36722510)
17. Gao, P, Scheibel S, D'A mour P, John MR, Rao SD, Schmidt-Gayk H, Cantor T. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14. (Pubitemid 32230589)
18. Monier-Faugè re MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor T, Malluche HH. Improved assessment of bone turnover by the PTH (1 - 84)/C-PTH fragments ratio in ESRD patients. Kidney Int 2001;60:460-8.
19. Tanaka M, Komaba H, Itoh K, Matsushita K, Matsushita K, Hamada Y, Fujii H, Fukagawa M. The whole-PTH/ intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 1:iii59 - 62.
20. Ljungdahl N, Haarhaus M, Linder C, Magnusson P. Comparison of 3 third-generation assays for bio-intact parathyroid hormone. Clin Chem 2006;52:903-4. (Pubitemid 43673278)